Cargando…

An International Survey on Grading, Diagnosis, and Management of Immune Effector Cell-Associated Hematotoxicity (ICAHT) Following CAR T-cell Therapy on Behalf of the EBMT and EHA

Hematological toxicity represents the most common grade ≥3 toxicity after chimeric antigen receptor (CAR) T-cell therapy. However, its underlying pathophysiology is incompletely understood and its grading and management remains ill-defined. To inform the forthcoming European Hematology Association/E...

Descripción completa

Detalles Bibliográficos
Autores principales:	Rejeski, Kai, Greco, Raffaella, Onida, Francesco, Sánchez-Ortega, Isabel, Bonini, Chiara, Sureda, Anna, Gribben, John G., Yakoub-Agha, Ibrahim, Subklewe, Marion
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Lippincott Williams & Wilkins 2023
Materias:	Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10145722/ https://www.ncbi.nlm.nih.gov/pubmed/37125259 http://dx.doi.org/10.1097/HS9.0000000000000889

Ejemplares similares

S260: IMMUNE EFFECTOR CELL ASSOCIATED HEMATOTOXICITY (ICAHT) FOLLOWING CAR T-CELL THERAPY: INTERNATIONAL SURVEY AND CONSENSUS GUIDELINES ON ITS GRADING, DIAGNOSIS, AND MANAGEMENT ON BEHALF OF EHA AND EBMT
por: Rejeski, Kai, et al.
Publicado: (2023)

The Renovated Face of EHA Classical Master Class: A Survey-based Evaluation on Behalf of the EHA Campus Working Group
por: Gurnari, Carmelo, et al.
Publicado: (2022)

Severe hematotoxicity after CD19 CAR-T therapy is associated with suppressive immune dysregulation and limited CAR-T expansion
por: Rejeski, Kai, et al.
Publicado: (2023)

The CAR-HEMATOTOX risk-stratifies patients for severe infections and disease progression after CD19 CAR-T in R/R LBCL
por: Rejeski, Kai, et al.
Publicado: (2022)

Practice harmonization workshops of EBMT: an expert-based approach to generate practical and contemporary guidelines within the arena of hematopoietic cell transplantation and cellular therapy
por: Yakoub-Agha, Ibrahim, et al.
Publicado: (2023)

The CAR-HEMATOTOX score as a prognostic model of toxicity and response in patients receiving BCMA-directed CAR-T for relapsed/refractory multiple myeloma
por: Rejeski, Kai, et al.
Publicado: (2023)

485. Improved Outcome of COVID-19 in CAR T Cell Treated Patients; results of a multicenter study on behalf of the European Society for Blood and Marrow Transplantation (EBMT) Infectious Diseases Working Party and the European Hematology Association (EHA) Lymphoma Group
por: Ljungman, Per, et al.
Publicado: (2023)

Safety and feasibility of stem cell boost as a salvage therapy for severe hematotoxicity after CD19 CAR T-cell therapy
por: Rejeski, Kai, et al.
Publicado: (2022)

Hematopoietic Stem Cell Transplantation for Combined Immunodeficiencies, on Behalf of IEWP-EBMT
por: Neven, Benedicte, et al.
Publicado: (2020)

Poor outcome of patients with COVID-19 after CAR T-cell therapy for B-cell malignancies: results of a multicenter study on behalf of the European Society for Blood and Marrow Transplantation (EBMT) Infectious Diseases Working Party and the European Hematology Association (EHA) Lymphoma Group
por: Spanjaart, Anne Mea, et al.
Publicado: (2021)

Poor Outcome of Patients with COVID-19 after CAR T-Cell Therapy for B-Cell Malignancies: Results from a Multicenter Study on Behalf of the European Society for Blood and Marrow Transplantation (EBMT) Infectious Diseases Working Party and the European Hematology Association (EHA) Lymphoma Group
por: Spanjaart, Anne Mea, et al.
Publicado: (2021)

Autologous hematopoietic cell transplantation for relapsed multiple myeloma performed with cells procured after previous transplantation–study on behalf of CMWP of the EBMT
por: Drozd-Sokołowska, Joanna, et al.
Publicado: (2022)

The first steps towards a diverse and inclusive EBMT: a position paper
por: Montoto, S., et al.
Publicado: (2022)

Personalized Treatment for Hematologic Diseases in Europe: An EHA Position Paper
por: Jäger, Ulrich, et al.
Publicado: (2020)

The EBMT activity survey on hematopoietic-cell transplantation and cellular therapy 2018: CAR-T’s come into focus
por: Passweg, Jakob R., et al.
Publicado: (2020)

Immune Reconstitution Following Autologous Hematopoietic Stem Cell Transplantation for Multiple Sclerosis: A Review on Behalf of the EBMT Autoimmune Diseases Working Party
por: Cencioni, Maria Teresa, et al.
Publicado: (2022)

Intestinal Microbiome in Hematopoietic Stem Cell Transplantation For Autoimmune Diseases: Considerations and Perspectives on Behalf of Autoimmune Diseases Working Party (ADWP) of the EBMT
por: Alexander, Tobias, et al.
Publicado: (2021)

The EHA2021 Annual Congress Award Winners: Celebrating Excellence in Hematology
por: Gribben, John, et al.
Publicado: (2021)

Access to Affordable Orphan Medicines in Europe: An EHA Position Paper
por: Merlini, Giampaolo, et al.
Publicado: (2020)

Fair Pricing of Innovative Medicines: An EHA Position Paper
por: Hagenbeek, Anton, et al.
Publicado: (2020)

Impact of the SARS-CoV-2 pandemic on hematopoietic cell transplantation and cellular therapies in Europe 2020: a report from the EBMT activity survey
por: Passweg, Jakob R., et al.
Publicado: (2022)

Leukemia relapse following unmanipulated haploidentical transplantation: a risk factor analysis on behalf of the ALWP of the EBMT
por: Piemontese, Simona, et al.
Publicado: (2019)

EU-Wide Access to High-quality, Affordable Precision Diagnostics: An EHA Position Paper
por: Macintyre, Elizabeth, et al.
Publicado: (2020)

The EBMT Immune Effector Cell Nursing Guidelines on CAR-T Therapy: A Framework for Patient Care and Managing Common Toxicities
por: Ellard, Rose, et al.
Publicado: (2022)

Carfilzomib, lenalidomide and dexamethasone followed by a second ASCT is an effective strategy in first relapse multiple myeloma: a study on behalf of the Chronic malignancies working party of the EBMT
por: Tilmont, Rémi, et al.
Publicado: (2023)

Organ complications after CD19 CAR T-cell therapy for large B cell lymphoma: a retrospective study from the EBMT transplant complications and lymphoma working party
por: Penack, Olaf, et al.
Publicado: (2023)

Inflammatory abrasion of hematopoietic stem cells: a candidate clue for the post-CAR-T hematotoxicity?
por: Sun, Ting, et al.
Publicado: (2023)

Diagnosis and Management of Secondary HLH/MAS Following HSCT and CAR-T Cell Therapy in Adults; A Review of the Literature and a Survey of Practice Within EBMT Centres on Behalf of the Autoimmune Diseases Working Party (ADWP) and Transplant Complications Working Party (TCWP)
por: Sandler, Robert David, et al.
Publicado: (2020)

Hematopoietic cell transplantation and cellular therapy survey of the EBMT: monitoring of activities and trends over 30 years
por: Passweg, Jakob R., et al.
Publicado: (2021)

Hematotoxicity and carcinogenicity of benzene.
por: Aksoy, M
Publicado: (1989)

S263: CYTOPENIAS, AGE AND CAR-HEMATOTOX SCORE PREDICT THE DEVELOPMENT OF POST CAR T-CELL THERAPY-RELATED MYELOID NEOPLASMS
por: Gurney, Mark, et al.
Publicado: (2023)

P1444: IMPACT OF CO-MORBIDITIES ON NON-RELAPSE MORTALITY AND CYTOKINE-RELEASE SYNDROME AFTER CD19 CAR-T CELL THERAPY - A RETROSPECTIVE STUDY FROM THE TCWP OF THE EBMT AND GOCART COALITION
por: Basak, G., et al.
Publicado: (2022)

The challenge of COVID-19 and hematopoietic cell transplantation; EBMT recommendations for management of hematopoietic cell transplant recipients, their donors, and patients undergoing CAR T-cell therapy
por: Ljungman, Per, et al.
Publicado: (2020)

Hematotoxicity and carcinogenicity of inhaled benzene.
por: Cronkite, E P, et al.
Publicado: (1989)

The EHA Research Roadmap: Anemias
por: Iolascon, Achille, et al.
Publicado: (2021)

Correction: The challenge of COVID-19 and hematopoietic cell transplantation: EBMT recommendations for management of hematopoietic cell transplant recipients, their donors, and patients undergoing CAR T-cell therapy
por: Ljungman, Per, et al.
Publicado: (2020)

The EHA Research Roadmap: Malignant Lymphoid Diseases
por: Dreyling, Martin, et al.
Publicado: (2022)

Unmanipulated haploidentical stem cell transplantation in adults with acute lymphoblastic leukemia: a study on behalf of the Acute Leukemia Working Party of the EBMT
por: Santoro, Nicole, et al.
Publicado: (2017)

General information for patients and carers considering haematopoietic stem cell transplantation (HSCT) for severe autoimmune diseases (ADs): A position statement from the EBMT Autoimmune Diseases Working Party (ADWP), the EBMT Nurses Group, the EBMT Patient, Family and Donor Committee and the Joint Accreditation Committee of ISCT and EBMT (JACIE)
por: Jessop, Helen, et al.
Publicado: (2019)

Hematotoxicity of deoxynivalenol in BALB/c mice
por: Chatopadhyay, Pronobesh, et al.
Publicado: (2011)

Cannot write session to /tmp/vufind_sessions/sess_dmvsh294ptrtccrc8gdac4makf